703 related articles for article (PubMed ID: 23974631)
1. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.
Ebina H; Misawa N; Kanemura Y; Koyanagi Y
Sci Rep; 2013; 3():2510. PubMed ID: 23974631
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
3. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
4. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
Bialek JK; Dunay GA; Voges M; Schäfer C; Spohn M; Stucka R; Hauber J; Lange UC
PLoS One; 2016; 11(6):e0158294. PubMed ID: 27341108
[TBL] [Abstract][Full Text] [Related]
5. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
6. Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.
Trejbalová K; Kovářová D; Blažková J; Machala L; Jilich D; Weber J; Kučerová D; Vencálek O; Hirsch I; Hejnar J
Clin Epigenetics; 2016; 8():19. PubMed ID: 26900410
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.
Hu W; Kaminski R; Yang F; Zhang Y; Cosentino L; Li F; Luo B; Alvarez-Carbonell D; Garcia-Mesa Y; Karn J; Mo X; Khalili K
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11461-6. PubMed ID: 25049410
[TBL] [Abstract][Full Text] [Related]
9. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
10. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
11. Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.
Li C; Wang HB; Kuang WD; Ren XX; Song ST; Zhu HZ; Li Q; Xu LR; Guo HJ; Wu L; Wang JH
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795436
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling.
Zhang Y; Arango G; Li F; Xiao X; Putatunda R; Yu J; Yang XF; Wang H; Watson LT; Zhang L; Hu W
BMC Med Genomics; 2018 Sep; 11(1):78. PubMed ID: 30200981
[TBL] [Abstract][Full Text] [Related]
13. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs.
Zhang Y; Yin C; Zhang T; Li F; Yang W; Kaminski R; Fagan PR; Putatunda R; Young WB; Khalili K; Hu W
Sci Rep; 2015 Nov; 5():16277. PubMed ID: 26538064
[TBL] [Abstract][Full Text] [Related]
15. A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG).
Huang H; Kong W; Jean M; Fiches G; Zhou D; Hayashi T; Que J; Santoso N; Zhu J
Nucleic Acids Res; 2019 Aug; 47(14):7333-7347. PubMed ID: 31165872
[TBL] [Abstract][Full Text] [Related]
16. Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus.
Campbell LA; Coke LM; Richie CT; Fortuno LV; Park AY; Harvey BK
Mol Ther; 2019 Jan; 27(1):151-163. PubMed ID: 30389355
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic application of CRISPR/Cas9 technologies for HIV.
Saayman S; Ali SA; Morris KV; Weinberg MS
Expert Opin Biol Ther; 2015 Jun; 15(6):819-30. PubMed ID: 25865334
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection.
Yin L; Hu S; Mei S; Sun H; Xu F; Li J; Zhu W; Liu X; Zhao F; Zhang D; Cen S; Liang C; Guo F
Hum Gene Ther; 2018 Nov; 29(11):1264-1276. PubMed ID: 29644868
[TBL] [Abstract][Full Text] [Related]
19. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
